Loading clinical trials...
Loading clinical trials...
Randomized Open-labeled Phase 2 Study of Maintenance Olaparib With or Without Durvalumab for DDR Gene Mutated Advanced Biliary Tract Cancer Following Platinum-based Chemotherapy
Conditions
Interventions
Durvalumab
Olaparib
Locations
1
South Korea
Asan Medical Center
Seoul, South Korea
Start Date
April 1, 2022
Primary Completion Date
December 30, 2025
Completion Date
December 30, 2026
Last Updated
January 28, 2025
NCT06921928
NCT06282575
NCT05489211
NCT07151118
NCT04900818
NCT07146646
Lead Sponsor
Asan Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions